An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice

Abstract Background Respiratory syncytial virus (RSV) is a leading viral respiratory pathogen in infants. The objective of this study was to generate RSV live-attenuated vaccine (LAV) candidates by removing the G-protein mucin domains to attenuate viral replication while retaining immunogenicity through deshielding of surface epitopes. Methods Two LAV candidates were generated from recombinant RSV A2-line19F by deletion of the G-protein mucin domains (A2-line19F-G155) or deletion of the G-protein mucin and transmembrane domains (A2-line19F-G155S). Vaccine attenuation was measured in BALB/c mouse lungs by fluorescent focus unit (FFU) assays and real-time polymerase chain reaction (RT-PCR). Immunogenicity was determined by measuring serum binding and neutralizing antibodies in mice following prime/boost on days 28 and 59. Efficacy was determined by measuring RSV lung viral loads on day 4 postchallenge. Results Both LAVs were undetectable in mouse lungs by FFU assay and elicited similar neutralizing antibody titers compared to A2-line19F on days 28 and 59. Following RSV challenge, vaccinated mice showed no detectable RSV in the lungs by FFU assay and a significant reduction in RSV RNA in the lungs by RT-PCR of 560-fold for A2-line19F-G155 and 604-fold for A2-line19F-G155S compared to RSV-challenged, unvaccinated mice. Conclusions Removal of the G-protein mucin domains produced RSV LAV candidates that were highly attenuated with retained immunogenicity.

[1]  S. Madhi,et al.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis , 2022, The Lancet.

[2]  Michael Koval,et al.  A medium composition containing normal resting glucose that supports differentiation of primary human airway cells , 2022, Scientific Reports.

[3]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[4]  J. Avner,et al.  Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic , 2021, Pediatrics.

[5]  M. van Boven,et al.  Population-based serology reveals risk factors for RSV infection in children younger than 5 years , 2021, Scientific Reports.

[6]  O. Ramilo,et al.  The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines , 2021, PLoS pathogens.

[7]  S. Delagrave,et al.  Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model. , 2020, Virology.

[8]  Puneet Juneja,et al.  Cryo-EM structure of the respiratory syncytial virus RNA polymerase , 2020, Nature Communications.

[9]  W. Martinet,et al.  Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity. , 2019, Virus research.

[10]  Christopher C. Stobart,et al.  A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences , 2019, Pathogens.

[11]  M. Moore,et al.  Enhancing the Thermostability and Immunogenicity of a Respiratory Syncytial Virus (RSV) Live-Attenuated Vaccine by Incorporating Unique RSV Line19F Protein Residues , 2017, Journal of Virology.

[12]  L. Kauvar,et al.  Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem , 2017, Journal of Virology.

[13]  B. Graham,et al.  A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation , 2016, Nature Communications.

[14]  B. Graham,et al.  A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats , 2016, Journal of Virology.

[15]  M. Moore,et al.  Reverse Genetics of Respiratory Syncytial Virus. , 2016, Methods in molecular biology.

[16]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[17]  R. Plemper,et al.  Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis , 2014, Journal of Virology.

[18]  Kartik Chandran,et al.  Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1 , 2014, mBio.

[19]  J. McLellan,et al.  Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.

[20]  R. Plemper,et al.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. , 2012, Virology.

[21]  P. Bates,et al.  Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein , 2010, PLoS pathogens.

[22]  B. Murphy,et al.  The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes , 2008, Journal of Virology.

[23]  R. Karron,et al.  The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. , 2007, Vaccine.

[24]  P. Wright,et al.  Growth of Respiratory Syncytial Virus in Primary Epithelial Cells from the Human Respiratory Tract , 2005, Journal of Virology.

[25]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.